Wall Street analyst estimates for Spyre Therapeutics, Inc. (SYRE): consensus price target, buy/hold/sell recommendations and forecasts for revenue and EPS for the upcoming fiscal years.
Spyre Therapeutics, Inc. is a biotechnology firm operating at the preclinical stage, dedicated to creating innovative treatments for individuals afflicted with inflammatory bowel disease (IBD). Among its pipeline candidates is SPY001, a human monoclonal immunoglobulin G1 antibody specifically engineered to target and bind with the a4ß7 integrin. This particular therapy is under development for addressing both ulcerative colitis and Crohn's disease, two forms of IBD.
Consensus price target
$119.89 (+21 % vs price $99.27)
between $107.00 and $130.00 · 9 targets published in the last quarter
Closing price, Nov 3
A twelve-month target is not a fair value: compare it with the range in the Valuation tab.
Revenue and EPS estimates
| Fiscal year | Revenue (average) | Revenue (low – high) | EPS (average) | Analysts |
|---|---|---|---|---|
| 2026E | $88,600 | $88,600 – $88,600 | -$2.72 | 11 |
| 2027E | $166,667 | $166,667 – $166,667 | -$3.50 | 11 |
| 2028E | $200,000 | $200,000 – $200,000 | -$4.13 | 11 |
Figures in USD · consensus as of November 1, 2026
Analyst Consensus
| Strong Buy | 0 |
| Buy | 12 |
| Hold | 1 |
| Sell | 0 |
| Strong Sell | 0 |
| Total analysts | 13 |
| Avg rating (−2 sell to +2 buy) | 0.92 |
Recent Earnings Surprises
| Date | EPS Actual | EPS Est. | vs Est. |
|---|---|---|---|
| 2026-11-03 | $-0.79 | ||
| 2026-08-04 | $-0.36 | $-0.76 | +52.6% |
| 2026-05-05 | $-0.74 | $-0.66 | -12.1% |
| 2026-02-19 | $-0.70 | $-0.66 | -6.1% |
| 2025-11-04 | $-0.15 | $-0.76 | +80.3% |
| 2025-08-05 | $-0.49 | $-0.73 | +32.9% |
| 2025-05-08 | $-0.74 | $-0.84 | +11.9% |
| 2025-02-28 | $-0.81 | $-0.89 | +9.0% |
Valuation Ratios
| Price / Book | 32.67 |
| Dividend Yield | 0.00% |
Income Statement (10y)
| Year | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $4.6M | $5.2M | $3.9M | 0 | 0 | $18.7M | $2.3M | $886,000 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | $901,000 | $1.6M | 0 | 0 | 0 | 0 | $171.7M |
| Gross Profit | 0 | 0 | 0 | -$901,000 | -$1.6M | $18.7M | $2.3M | $886,000 | 0 | -$171.7M |
| Research & Development | $18.1M | $22.8M | $36.7M | $64.6M | $59.6M | $57.1M | $58.6M | $89.5M | $162.8M | $171.7M |
| Selling, General & Admin | $8.4M | $10.1M | $12.6M | $14.8M | $20.2M | $27.3M | $28.5M | $39.9M | $45.8M | $47.9M |
| Operating Expenses | $26.5M | $32.9M | $49.4M | $79.4M | $79.9M | $84.4M | $87.1M | $243.2M | $208.6M | $37.9M |
| Operating Income | -$21.9M | -$27.7M | -$45.5M | -$80.3M | -$81.5M | -$65.6M | -$84.8M | -$242.3M | -$208.6M | -$209.6M |
| EBITDA | -$21.8M | -$27.4M | -$45.2M | -$77.4M | -$79.9M | -$64.1M | -$82.0M | -$127.8M | -$208.0M | -$209.6M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Pre-tax Income | -$21.7M | -$27.2M | -$44.3M | -$78.3M | -$80.9M | -$65.7M | -$84.0M | -$338.8M | -$208.0M | -$155.2M |
| Income Tax | 0 | 0 | 0 | 0 | 0 | $141,000 | -$136,000 | -$26,000 | $51,000 | -$15,000 |
| Net Income | -$21.7M | -$27.2M | -$44.3M | -$78.3M | -$80.9M | -$65.8M | -$83.8M | -$338.8M | -$208.0M | -$155.2M |
| EPS | -$55.40 | -$45.01 | -$53.25 | -$61.23 | -$37.89 | -$25.02 | -$24.86 | -$46.15 | -$3.18 | -$1.98 |
| EPS (Diluted) | -$55.40 | -$45.01 | -$53.25 | -$61.23 | -$37.89 | -$25.02 | -$24.86 | -$46.15 | -$3.18 | -$1.98 |
| Shares Outstanding (Diluted) | 391,669 | 605,127 | 832,902 | 1.3 M | 2.1 M | 2.6 M | 3.4 M | 6.9 M | 47.0 M | 64.1 M |
Price
| Price | $99.27 (closing price, November 3, 2026) |
| Market Cap | $9.2B |
| Exchange | NASDAQ |
| Country | US |
Related companies: ABVX · VRTX · 0QZU.L · REGN · MRNA · 0R2M.L · ARGX · 0QNO.L
Explore sector: Healthcare · Biotechnology
More sections of SYRE: Overview · Financials · Valuation · Statistics · Technical · Ownership · News · Events
Discover more: Weekly Radar: the S&P 500 through the Buffett and Lynch methods · Companies that pass the Buffett method · Companies that pass the Lynch method · Stocks that pass Graham's defensive investor test today · Investment Academy — learn to analyze stocks